21 / 40
Olaparib
(SOLO-2)
gBRCAmut
Niraparib
(NOVA)
gBRCAmut
Niraparib
(NOVA)
Non-gBRCAmut
TFST
HR 0.28
, 95% CI 0.21–0.38
27.9 versus 7.1 months
HR 0.31
, P<0.0001
21.0 vs 8.4 months
HR 0.55
, P<0.0001
11.8 vs 7.2 months
PFS2
HR 0.50
, 95% CI 0.34–0.72
NR versus 18.4 months
HR 0.48
(0.27-0.85)
HR 0.74
(0.51-1.06)
TSST
HR 0.37
, 95% CI 0.26–0.53
NR versus 18.2 months
HR 0.48
(0.28-0.82)
HR 0.69
(0.49-0.96)
TFST: Time to First Subsequent Therapy
PFS2: progression free survival to subsequent therapy
TSST: Time to Second Subsequent Therapy
Maintenance with PARP inhibitors
SOLO-2 and NOVA Secondary end-points: Long-term benefit